• 1. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

Introduction to 4-Bromo-1-(methoxymethoxy)-2-(trifluoromethoxy)benzene (CAS No. 2918893-47-5)

4-Bromo-1-(methoxymethoxy)-2-(trifluoromethoxy)benzene, identified by its Chemical Abstracts Service (CAS) number 2918893-47-5, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and agrochemical research. This compound belongs to the class of brominated aromatic ethers, characterized by its bromine substituent and multiple ether functionalities. The presence of both methoxymethoxy and trifluoromethoxy groups imparts unique electronic and steric properties, making it a valuable intermediate in the synthesis of more complex molecules.

The structural configuration of 4-Bromo-1-(methoxymethoxy)-2-(trifluoromethoxy)benzene is highly versatile, enabling its use in various synthetic pathways. The bromine atom at the 4-position serves as a reactive handle for further functionalization, while the electron-withdrawing nature of the trifluoromethoxy group influences the reactivity of the aromatic ring. This balance of electronic and steric effects makes it an attractive building block for medicinal chemists seeking to develop novel bioactive compounds.

In recent years, there has been a surge in interest regarding fluorinated aromatic compounds due to their enhanced metabolic stability, improved binding affinity, and increased lipophilicity in drug candidates. The incorporation of fluorine atoms, particularly in the form of trifluoromethoxy groups, has been shown to modulate pharmacokinetic properties, leading to more effective therapeutic agents. 4-Bromo-1-(methoxymethoxy)-2-(trifluoromethoxy)benzene exemplifies this trend, as its structure allows for the exploration of fluorinated derivatives with potential applications in oncology, anti-inflammatory drugs, and central nervous system (CNS) therapies.

One of the most compelling aspects of 4-Bromo-1-(methoxymethoxy)-2-(trifluoromethoxy)benzene is its role as a precursor in the synthesis of small-molecule inhibitors targeting specific biological pathways. For instance, researchers have utilized this compound to develop kinase inhibitors, which are crucial in treating various cancers. The bromine atom can be readily displaced by nucleophiles, enabling the introduction of diverse functional groups that can fine-tune the interaction with biological targets. Additionally, the presence of both ether moieties provides opportunities for further derivatization, allowing chemists to tailor properties such as solubility and bioavailability.

The pharmaceutical industry has increasingly leveraged fluorinated aromatics to enhance drug efficacy and reduce off-target effects. A notable example is the development of tyrosine kinase inhibitors (TKIs) used in cancer therapy. These inhibitors often require precise structural features to bind effectively to their protein targets. 4-Bromo-1-(methoxymethoxy)-2-(trifluoromethoxy)benzene has been employed in synthesizing novel TKIs by serving as a core scaffold. The electron-withdrawing influence of the trifluoromethoxy group helps stabilize negative charges developed during binding interactions, while the bromine atom facilitates late-stage modifications to optimize potency.

Moreover, agrochemical researchers have also explored derivatives of 4-Bromo-1-(methoxymethoxy)-2-(trifluoromethoxy)benzene for developing advanced crop protection agents. Fluorinated compounds are known for their improved resistance to degradation and enhanced activity against pests and pathogens. By modifying the structure of this benzene derivative, scientists have created herbicides and fungicides that offer greater efficacy while maintaining environmental safety profiles.

The synthetic methodologies involving 4-Bromo-1-(methoxymethoxy)-2-(trifluoromethoxy)benzene are diverse and well-documented. One common approach involves nucleophilic aromatic substitution (SNAr), where the bromine atom is replaced by various nucleophiles such as alkoxides or amines. This reaction allows for the introduction of different functional groups at strategic positions on the aromatic ring. Additionally, palladium-catalyzed cross-coupling reactions have been utilized to construct more complex molecular architectures from this precursor.

Recent advances in flow chemistry have further expanded the synthetic possibilities of 4-Bromo-1-(methoxymethoxy)-2-(trifluoromethoxy)benzene. Flow reactors provide controlled reaction conditions, enabling higher yields and cleaner reactions compared to traditional batch processing. This technology has been particularly beneficial in scaling up syntheses while minimizing waste generation—a critical consideration in modern drug development.

The impact of fluorinated aromatics on medicinal chemistry cannot be overstated. Compounds like those derived from 4-Bromo-1-(methoxymethoxy)-2-(trifluoromethoxy)benzene continue to drive innovation across multiple therapeutic areas. By leveraging their unique structural features, researchers are uncovering new treatments for diseases that were previously difficult to address with conventional therapeutics.

In conclusion,4-Bromo-1-(methoxymethoxy)-2-(trifluoromethoxy)benzene (CAS No. 2918893-47-5) represents a cornerstone compound in modern synthetic chemistry with far-reaching implications for pharmaceuticals and agrochemicals. Its versatile structure and reactivity make it an indispensable tool for chemists striving to develop next-generation bioactive molecules that meet stringent therapeutic requirements.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)